04 April, 2020
5 Min Read
“Arogya Sanjeevani”: IRDAI
Part of: GS Prelims and GS-II-Regulatory bodies
The COVID-19 hospitalization cases are increasing which posing financial burden on patients or their families due to hospitalization expenses. As a financial relief measure to the COVID-19 positive cases, Insurance Regulatory and Development Authority of India (IRDAI) has made the coverage of hospitalization treatment costs of COVID-19 mandatory under standard health insurance product “Arogya Sanjeevani”. Apart from this, Indemnity based health insurance products offered by all general and health insurance companies will also cover the costs of hospitalization treatment on account of covid-19.
The objective behind this move is support individuals who are seeking treatment in private hospitals as in government hospitals the expenses the paid by government itself.
About Arogya Sanjeevani:
IRDAI in January, 2020 mandated all health and general insurance companies to offer a standard product called the Arogya Sanjeevani policy starting 1st April 2020. In this regard 29 general and health Insurance companies received clearance to market Arogya Sanjeevani.
Insurance Regulatory and Development Authority of India or the IRDAI is the apex body responsible for regulating and developing the insurance industry in India. It is an autonomous body. It was established by an act of Parliament known as the Insurance Regulatory and Development Authority Act, 1999. IRDAI is headquartered in Hyderabad in Telangana. Prior to 2001, it was headquartered in New Delhi. The organization fought for an increase in the FDI limit in the insurance sector to 49% from the previous 26%. The FDI cap was hiked to 49% in July of 2014.
Establishment– 1999 (autonomous body), 2000 (statutory body)
Headquarters– Hyderabad, Telangana
Chairman– Subhash C. Khuntia
Copyright© Aspire IAS Academy. All rights reserved. Powered by CLT Technologies & Edu-Publishers Private Limited.